A Phase 4 interventional study of MetFORMIN and Matching Placebo in Polycystic Ovary Syndrome (PCOS) Women, sponsored by Jerash Private University. Completed at 1 site in Jordan. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Jerash Private University · Phase 4, Interventional, and Treatment
Polycystic ovary syndrome (PCOS) is a common condition associated with metabolic abnormalities, including insulin resistance, impaired glucose regulation, and abnormal lipid levels. Metformin is commonly used to improve metabolic outcomes in women with PCOS, while lifestyle modification and behavioral education are important components of PCOS management. This study evaluates whether metformin, alone or combined with a theory-based behavioral educational program, is associated with changes in metabolic, vitamin B12, iron-status, erythropoietin, and hematological parameters compared with matching placebo.
This is a prospective, three-arm, parallel-group randomized controlled trial conducted among women aged 18-40 years with specialist-confirmed PCOS in Ministry of Health obstetrics and gynecology clinics in Jordan. A total of 900 participants were initially randomized in a 1:1:1 ratio to receive matching placebo, metformin, or metformin combined with a theory-based behavioral educational program. The metformin groups received 1500 mg/day, administered as 500 mg three times daily, for six months. The combined intervention group additionally received five structured educational sessions addressing PCOS self-management, healthy dietary practices, physical activity, weight and waist management, metformin adherence, sleep, stress management, problem solving, and maintenance of healthy behaviors.
Clinical and laboratory outcomes were assessed at baseline and after six months. The primary outcomes include changes in anthropometric, metabolic, vitamin B12, iron-status, erythropoietic, and hematological parameters. Changes in PCOS-related knowledge and lifestyle practices were also evaluated among participants receiving the combined intervention.
This study is a prospective, three-arm, parallel-group randomized controlled trial conducted among women diagnosed with polycystic ovary syndrome (PCOS). The study was conducted from August 2025 to February 2026 in obstetrics and gynecology clinics affiliated with the Ministry of Health, Jordan. The intervention and follow-up period lasted six months.
A total of 900 eligible participants were initially randomized in a 1:1:1 ratio to one of three study groups: a matching placebo group, a metformin group, and a combined metformin plus theory-based behavioral educational intervention group. All participants received routine clinical care for PCOS.
Participants assigned to the matching placebo group received routine clinical care together with matching placebo tablets identical to the metformin tablets in appearance, size, and form. Participants in the metformin group received routine clinical care together with metformin at a total daily dose of 1500 mg, administered as 500 mg three times daily, for six months. Participants in the combined intervention group received the same metformin regimen together with a structured theory-based behavioral educational program.
The behavioral educational intervention was grounded in Bandura's Self-Efficacy Theory and incorporated educational and lifestyle domains relevant to PCOS self-management. The program consisted of five structured sessions of approximately 60 minutes each. The sessions addressed understanding PCOS and self-management; healthy dietary practices; physical activity, sedentary behavior, and weight and waist management; metformin adherence, metabolic health, and symptom monitoring; and sleep, stress management, problem solving, and maintenance of behavioral changes. Individualized education, practical examples, achievable goals, self-monitoring, reinforcement, and follow-up contacts were incorporated to support behavioral change.
Clinical and laboratory assessments were performed at baseline and at six months. The primary objective was to compare changes from baseline to six months among the three study groups in anthropometric parameters, metabolic parameters, vitamin B12, iron-status biomarkers, erythropoietin, and hematological indices. Metabolic assessments included measures of glucose regulation and insulin resistance and lipid parameters. Iron-status assessments included serum iron, total iron-binding capacity, transferrin saturation, and ferritin. Hematological assessments included hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, red cell distribution width, white blood cell count, differential leukocyte counts, and platelet count.
A secondary objective was to evaluate changes in PCOS-related knowledge and lifestyle practices among participants receiving the combined metformin and theory-based behavioral educational intervention. Knowledge domains included the definition of PCOS, causes and risk factors, signs and symptoms, complications, and treatment and management. Lifestyle domains included dietary practices, physical activity, leisure activities, and sleep.
The study was designed to provide a controlled comparison of routine care with matching placebo, metformin therapy, and metformin combined with structured behavioral education. Participants receiving the educational intervention could not be blinded to the educational component because they were aware of their participation in the program. Standardized procedures were used for clinical assessment, laboratory measurements, data collection, and statistical analysis.
956 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
This study's enrollment of 900 is above the median of 70 across 697 interventional studies indexed under Polycystic Ovary Syndrome.
Browse Polycystic Ovary Syndrome studies →Jerash Private University is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received routine clinical care together with matching placebo tablets identical to the metformin tablets in appearance, size, and form for six months. They did not receive study-prescribed metformin or the structured theory-based behavioral educational intervention.
Drug: Matching Placebo
Participants received routine clinical care together with metformin at a total daily dose of 1500 mg, administered as 500 mg three times daily, for six months. They did not receive the structured theory-based behavioral educational intervention.
Drug: MetFORMIN
Participants received routine clinical care together with metformin at a total daily dose of 1500 mg, administered as 500 mg three times daily, for six months, plus a structured theory-based behavioral educational program. The program consisted of five structured sessions addressing PCOS self-management, healthy dietary practices, physical activity, sedentary behavior, weight and waist management, metformin adherence, metabolic health, sleep, stress management, problem solving, and maintenance of behavioral changes.
Drug: MetFORMIN · Behavioral: Theory-Based Behavioral Educational Program
Metformin was administered at a total daily dose of 1500 mg, given as 500 mg three times daily, for six months.
Matching placebo tablets identical to the metformin tablets in appearance, size, and form were administered for six months.
A structured behavioral educational program grounded in Bandura's Self-Efficacy Theory was provided to participants in the combined intervention group. The program consisted of five structured sessions addressing PCOS self-management, healthy dietary practices, physical activity and sedentary behavior, weight and waist management, metformin adherence, metabolic health, sleep, stress management, problem solving, and maintenance of behavioral changes.
Change in Body Mass Index (BMI) From Baseline to 6 Months
Change in body mass index (BMI) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Serum Insulin From Baseline to 6 Months
Change in serum insulin from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in HOMA-IR From Baseline to 6 Months
Change in homeostasis model assessment of insulin resistance (HOMA-IR) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Total Cholesterol (TC) From Baseline to 6 Months
Change in total cholesterol (TC) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Triglycerides (TG) From Baseline to 6 Months
Change in triglycerides (TG) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to 6 Months
Change in low-density lipoprotein cholesterol (LDL-C) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to 6 Months
Change in high-density lipoprotein cholesterol (HDL-C) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Serum Vitamin B12 From Baseline to 6 Months
Change in serum vitamin B12 concentration from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Serum Iron From Baseline to 6 Months
Change in serum iron concentration from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Serum Ferritin From Baseline to 6 Months
Change in serum ferritin concentration from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Total Iron-Binding Capacity (TIBC) From Baseline to 6 Months
Change in total iron-binding capacity (TIBC) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Transferrin Saturation (TSAT) From Baseline to 6 Months
Change in transferrin saturation (TSAT) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Serum Erythropoietin (EPO) From Baseline to 6 Months
Change in serum erythropoietin (EPO) concentration from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Hemoglobin (Hb) From Baseline to 6 Months
Change in hemoglobin (Hb) concentration from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Hematocrit (Hct) From Baseline to 6 Months
Change in hematocrit (Hct) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Mean Corpuscular Volume (MCV) From Baseline to 6 Months
Change in mean corpuscular volume (MCV) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Mean Corpuscular Hemoglobin (MCH) From Baseline to 6 Months
Change in mean corpuscular hemoglobin (MCH) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Mean Corpuscular Hemoglobin Concentration (MCHC) From Baseline to 6 Months
Change in mean corpuscular hemoglobin concentration (MCHC) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Red Cell Distribution Width (RDW) From Baseline to 6 Months
Change in red cell distribution width (RDW) from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in White Blood Cell (WBC) Count From Baseline to 6 Months
Change in neutrophil count from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Lymphocyte Count From Baseline to 6 Months
Change in lymphocyte count from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Eosinophil Count From Baseline to 6 Months
Change in eosinophil count from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Basophil Count From Baseline to 6 Months
Change in basophil count from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in Platelet Count From Baseline to 6 Months
Change in platelet count from baseline to 6 months among participants assigned to the matching placebo, metformin, or metformin plus theory-based behavioral education groups.
Time frame: Baseline to 6 months
Change in PCOS-Related Knowledge and Lifestyle Practices From Baseline to 6 Months
Change from baseline to 6 months in PCOS-related knowledge and lifestyle-practice scores among participants receiving metformin combined with the theory-based behavioral educational program. The assessment included PCOS-related knowledge and lifestyle domains covering food habits, physical activity, leisure time, and sleep pattern.
Time frame: Baseline to 6 months
Plan to share: No — Individual participant data (IPD) will not be shared with other researchers. Data will be retained by the research team and used for the purposes of the registered study and related scientific reporting.
No publications or documents are linked to this record.
Ran from Aug 2026 to primary completion in Aug 2026, 0 months.
Of 41 non-industry phase 4 interventional studies under Polycystic Ovary Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 45. This study's 0 months is below that.
Counting every sponsor, half of 42 studies reached it within 25 months; a quarter within 11 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Jerash Private University